MFW
ALNY icon

Meristem Family Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Meristem Family Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,344
Closed -$254K – 392
2021
Q3 		$254K Buy
+1,344
New +$252K 0.02% 347

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Meristem Family Wealth's ALNY Position: Q4 2021 in Review

Meristem Family Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 1,344 shares — an estimated $254K sold.

Meristem Family Wealth first reported a position in ALNY in Q3 2021 and held it in 1 quarter. The position peaked at $254K in Q3 2021. 434 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Meristem Family Wealth reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Meristem Family Wealth sold 1,344 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $254K.
  • Meristem Family Wealth first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Meristem Family Wealth's Alnylam Pharmaceuticals position peaked at $254K in Q3 2021.
  • 434 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Meristem Family Wealth's 13F filing for Q4 2021, filed 10 Feb 2022.